Literature DB >> 27037683

Long-term human primary hepatocyte cultures in a microfluidic liver biochip show maintenance of mRNA levels and higher drug metabolism compared with Petri cultures.

Rachid Jellali1, Thibault Bricks1, Sébastien Jacques2, Marie-José Fleury1, Patrick Paullier1, Franck Merlier3, Eric Leclerc1,4.   

Abstract

Human primary hepatocytes were cultivated in a microfluidic bioreactor and in Petri dishes for 13 days. mRNA kinetics in biochips showed an increase in the levels of CYP2B6, CYP2C19, CYP2C8, CYP3A4, CYP1A2, CYP2D6, HNF4a, SULT1A1, UGT1A1 mRNA related genes when compared with post extraction levels. In addition, comparison with Petri dishes showed higher levels of CYP2B6, CYP2C19, CYP2C8, CYP3A4, CYP1A2, CYP2D6 related genes at the end of culture. Functional assays illustrated a higher urea and albumin production over the period of culture in biochips. Bioreactor drug metabolism (midazolam and phenacetin) was not superior to the Petri dish after 2 days of culture. The CYP3A4 midazolam metabolism was maintained in biochips after 13 days of culture, whereas it was almost undetectable in Petri dishes. This led to a 5000-fold higher value of the metabolic ratio in the biochips. CYP1A2 phenacetin metabolism was found to be higher in biochips after 5, 9 and 13 days of culture. Thus, a 100-fold higher metabolic ratio of APAP in biochips was measured after 13 days of perfusion. These results demonstrated functional primary human hepatocyte culture in the bioreactor in a long-term culture.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27037683     DOI: 10.1002/bdd.2010

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

1.  A glass-based, continuously zonated and vascularized human liver acinus microphysiological system (vLAMPS) designed for experimental modeling of diseases and ADME/TOX.

Authors:  Xiang Li; Subin M George; Lawrence Vernetti; Albert H Gough; D Lansing Taylor
Journal:  Lab Chip       Date:  2018-08-21       Impact factor: 6.799

2.  Recent Advances in Body-on-a-Chip Systems.

Authors:  Jong Hwan Sung; Ying I Wang; Narasimhan Narasimhan Sriram; Max Jackson; Christopher Long; James J Hickman; Michael L Shuler
Journal:  Anal Chem       Date:  2018-12-11       Impact factor: 6.986

3.  Prediction of hepatic drug clearance with a human microfluidic four-cell liver acinus microphysiology system.

Authors:  Courtney Sakolish; Yu-Syuan Luo; Alan Valdiviezo; Lawrence A Vernetti; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicology       Date:  2021-09-17       Impact factor: 4.221

4.  Current Trends in Microfluidics and Biosensors for Cancer Research Applications.

Authors:  David Caballero; Rui L Reis; Subhas C Kundu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 5.  Joint-on-chip platforms: entering a new era of in vitro models for arthritis.

Authors:  Carlo Alberto Paggi; Liliana Moreira Teixeira; Séverine Le Gac; Marcel Karperien
Journal:  Nat Rev Rheumatol       Date:  2022-01-20       Impact factor: 32.286

6.  Comparison of gene expression and biotransformation activity of HepaRG cells under static and dynamic culture conditions.

Authors:  Loes P M Duivenvoorde; Jochem Louisse; Nicole E T Pinckaers; Tien Nguyen; Meike van der Zande
Journal:  Sci Rep       Date:  2021-05-14       Impact factor: 4.379

7.  Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver's Extracellular Matrix.

Authors:  Taha Messelmani; Anne Le Goff; Zied Souguir; Victoria Maes; Méryl Roudaut; Elodie Vandenhaute; Nathalie Maubon; Cécile Legallais; Eric Leclerc; Rachid Jellali
Journal:  Bioengineering (Basel)       Date:  2022-09-05

Review 8.  Implementing organ-on-chip in a next-generation risk assessment of chemicals: a review.

Authors:  Katharina S Nitsche; Iris Müller; Sophie Malcomber; Paul L Carmichael; Hans Bouwmeester
Journal:  Arch Toxicol       Date:  2022-02-01       Impact factor: 5.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.